 |
|
Angiogenesis Panel 1 (human) Kit
|
| Angiogenesis markers consist mainly of proangiogenic proteins. These are potential prognostic markers for disease activity and indicators of response to chemotherapy. Several different strategies have been designed to target vascular endothelial growth factor receptor (VEGFR) signal transduction. Several VEGF-neutralizing antibodies have been successful in combination with chemotherapy to limit angiogenesis and tumor progression. Other strategies to target the VEGF/VEGFR pathway include soluble VEGFRs (Traps), receptor tyrosine-kinase inhibitors that target VEGFR2/Flk-1, and neutralizing aptamers. Despite the success of anti-angiogenic therapy using VEGF inhibitors for many cancer patients, significant challenges remain. Therefore, it would be desirable to have reliable markers to identify patients who are most likely to respond to anti-VEGF treatment. Furthermore, a better understanding of signaling pathways in tumor angiogenesis, in addition to VEGF-receptors signaling, may help achieve an even more effective anticancer therapy. The Angiogeneis Panel 1 (human) Kit provides the assay-specific components for the quantitative determination of up to seven of the following angiogenesis biomarkers: VEGF, VEGF-C, VEGF-D, Tie-2, sFlt-1, PlGF, and bFGF. This kit may be used for the analysis of all or any combination of these biomarkers in human serum, plasma, and cell supernatant. |
|
K15190D-4
|
Angiogenesis Panel 1 (human) Kit |
25 plates |
|
K15190D-2
|
Angiogenesis Panel 1 (human) Kit |
5 plates |
|
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.
Mathew, P., Wen, S., Morita, S., Thall, P.F.
|
J Interferon Cytokine Res. |
2011 |
|
Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.
Cai, J., Hong, Y., Weng, C., Tan, C., Imperato-McGinley, J., Zhu, Y.S.
|
Am J Physiol Heart Circ Physiol. |
2011 |
|
Blood protein concentrations in the first two postnatal weeks associated with early postnatal blood gas derangements among infants born before the 28th week of gestation. The ELGAN Study.
Leviton, A., Allred, E.N., Kuban, K.C., Dammann, O., Fichorova, R.N., O'Shea, T.M., Paneth, N.; for the ELGAN Study Co-Investigators.
|
Cytokine. |
2011 |
|
Persistence after birth of systemic inflammation associated with umbilical cord inflammation.
Leviton, A., Hecht, J.L., Allred, E.N., Yamamoto, H., Fichorova, R.N., Dammann, O.; for the ELGAN Study Investigators.
|
J Reprod Immunol. |
2011 |
|
Cluster Analysis of Placental Inflammatory Proteins Can Distinguish Preeclampsia from Preterm Labor and Premature Membrane Rupture in Singleton Deliveries Less Than 28 Weeks of Gestation.
Faupel-Badger, J.M., Fichorova, R.N., Allred, E.N., Hecht, J.L., Dammann, O., Leviton, A., McElrath, T.F.
|
Am J Reprod Immunol. |
2011 |
|
|
|
|
 |
| Price |
Please call for price |
| Size |
1 plate |
| Catalog No. |
K15190D-1 |
| Availability |
Usually ships in 1-3 days |
|
Home
Products
K15190D-1
